English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
Radisson Announces Exercise of Warrants
Nov 18, 2025 06:29 HKT
Mazda Begins Demonstration Experiment of Onboard CO2 Capture System
Nov 17, 2025 23:38 HKT
Pushing Hydrogen Engine Technology to New Heights in the Super Taikyu Series Final Race
Nov 17, 2025 23:00 HKT
Graid Technology 完成與英特爾 VROC 的授權協議,拓展其在企業儲存解決方案領域的領導地位
Nov 17, 2025 23:00 HKT
Fujitsu launches business creation lab in collaboration with AWS Japan
Nov 17, 2025 22:41 HKT
NTT DOCOMO Achieves Successful Outdoor Trial of AI-Driven Wireless Interface Toward 6G
Nov 17, 2025 22:05 HKT
Graid Technology Finalizes Intel VROC Licensing Agreement, Expanding Leadership in Enterprise Storage Solutions
Nov 17, 2025 22:00 HKT
JBM Healthcare Announces FY2026 Interim Results
Nov 17, 2025 21:43 HKT
健倍苗苗公佈二零二六財政年度中期業績
Nov 17, 2025 21:43 HKT
健倍苗苗公布二零二六财政年度中期业绩
Nov 17, 2025 21:43 HKT
Destinator Earns the Highest Rating of Five Stars in 2025 ASEAN NCAP
Nov 17, 2025 21:32 HKT
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
Nov 17, 2025 21:08 HKT
OBI-902 has been granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Nov 17, 2025 21:00 HKT
NEC Advances Research Information Infrastructure for Open Science
Nov 17, 2025 20:38 HKT
Mitsubishi Shipbuilding Delivers Large Car Ferry KEYAKI to Shin Nihonkai Ferry and Japan Railway Construction, Transport and Technology Agency
Nov 17, 2025 20:00 HKT
Indonesia's TASPEN Fulfills Global Mandate, Delivering Full Benefits to Late Diplomat's Family
Nov 17, 2025 20:00 HKT
OBI-902 獲美國 FDA 審核通過治療膽管癌的「孤兒藥」資格認定
Nov 17, 2025 20:00 HKT
OBI-902获美国FDA审核通过用于治疗胆管癌的“孤儿药”资格认定
Nov 17, 2025 20:00 HKT
OBI-902 has been granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Nov 17, 2025 20:00 HKT
SuperX AI Technology Limited任命企业科技资深领军人物黄陈宏博士为董事局主席兼CEO 加速全球AI基础设施布局
Nov 17, 2025 19:53 HKT
<< Previous Next >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: